The effect of immunosuppressive and immunomodulatory drugs in a cellular model of brain inflammation: involvement of nitric oxide-mediated neuronal death

Cindy Duchemin, Emile Andriambeloson, Stéphanie Wagner

NEUROFIT SAS, boulevard Sébastien Brant - Bioparc Parc d'Innovation, 67400 ILLKIRCH, FRANCE - www.neurofit.com

Introduction

Neuroinflammation is now recognized as a critical process in different neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, stroke and multiple sclerosis. Microglia and astrocytes are key players in neuroinflammation since they release a wide variety of proinflammatory mediators, including nitric oxide (NO).

Glia-derived nitric oxide (NO) has been demonstrated to be a key effector responsible for the neurodegeneration following stimulation of a mixed culture of neurons, microglia, and astrocytes.1

(¹ The Journal of Neuroscience, September 1, 2001, 21(17):6480–6491)

Objectives

- To study the correlation between suppression of glia-derived NO and the neuroprotection induced by immunosuppressive (dexamethasone) and immunomodulatory (doramapimod) drugs.
- To investigate the contribution of other inflammatory mediators such as TNF- α and IL-1 β (NO-independent pathways) in the neuronal death.

Experimental design

Glia neuron culture from the mesencephalic brain of rat embryos (day 15 of gestation).

- Measure of death of dopaminergic neurons by immunostaining of Tyrosine Hydroxylase-positive neurons (TH-positive neurons)
- Measure of IL-1 β and TNF- α release by ELISA
- Measure of NO production by Griess reaction



Kev points

NEURC PRECLINICAL RESEARCH

NO - dependent and independent pathways are involved in the neuronal death observed in LPS stimulated cocultures.

Inhibition of NO production alone is not sufficient to prevent the neurodegeneration. The magnitude of change in production of NO-independent mediators counterbalances the potential beneficial effect of NO pathway inhibition during the inflammatory process.

Figure 1: Dexamethasone (immunosuppressor)

Figure 2: Doramapimod (immunomodulator)

1_{µ1} 10_{µ1}

Figure 3: Resveratrol (antioxidant)

NO

Resveratrol 15.4 30.4 60.4 100.4

350

300

100

225

200

175

150

125

100

75

50

25

0

LPS

LPS-stimulated IL-1β release (%)

LPS

Doramapimod

IL-1β

Resveratrol 15 30 30 60 100

ଡୁ ଛି 250

stimulate release (5

LPS-€ L-1β I

NO

100

LPS-stimulated NO release (%) 09 09 08

20

100

80

60

40

20

100 -

80

60

40 -

20

LPS

LPS-stimulated NO release (%)

LPS

Doramapimod

LPS-stimulated NO release (%)



IL-1B $TNF-\alpha$ Cell death 200 120 110 175-100 150 90 -80 -LPS-stimulate NF-α release (125 70. 100 28 60 50 Ξ 30 20 10 1 PS 1 PS 1_µ, 10_µ 1_{µ1} 10_{µ1} Doramapimod 0.1µm 1µm 10µm Doramapimod

LPS

Resveratrol 15 30 30 60 100



LPS

Resveratrol 15 Jan 30 M 60 M 100 M

Dexamethasone markedly reduced the release of NO as well as IL-16 and TNF-α.

Dexamethasone fully prevented LPS-induced neuronal death.

Doramapimod

fully suppressed NO production but dramatically stimulated the release of IL-1β (up to 2.5 times higher than under the control LPS condition).

Doramapimod

did not prevent LPS-induced neuronal death.

Resveratrol markedly reduced NO production but dramatically stimulated the release of both IL- 1β and TNF- α (1.3 times higher than under the control LPS condition).

Resveratrol partially. but significantly, LPSprevented induced neuronal death